- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Carol Lynch: Addressing Misinformation About Biosimilars
Carol Lynch, president of Sandoz US and head of North America, discusses which stakeholders have a role in addressing misinformation about biosimilars.
Transcript:
Who is responsible for addressing misinformation campaigns about biosimilars, and what can be done to stop them?
I think we all need to take on the task of tackling misinformation that’s out there, because I think, at best, it can lead to confusion for all stakeholders, and at worst, it can actually cause doubt about the safety and efficacy of biosimilars.
So, I think that from an FDA perspective they can definitely set out and help us with that. I think it’s on manufacturers to step up, but also the other players in the industry as well, so for example the medical societies, industry associations like [Association for Accessible Medicines] and Medicines for Europe, all play an important role in making sure that fair and balanced information is available to all stakeholders.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
